<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637869</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>COVID-19 hospitalization and mortality in community-dwelling racially and ethnically diverse persons living with dementia.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.18230</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Community-dwelling persons living with dementia (PLWD) are vulnerable to COVID-19 infection, severity, and mortality due to the high prevalence of comorbidities, reliance on caregivers, and potential inability to employ risk reduction measures, among other factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a retrospective cohort of Medicare Fee-For-Service beneficiaries enrolled from January 2018 to September 2020 (n&#xa0;=&#xa0;13,068,583), a comparison cohort from January 2019 to April 2021 (n&#xa0;=&#xa0;13,250,297), and logistic regression to estimate the effect of dementia on COVID-19 hospitalization and mortality in community-dwelling older persons.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">COVID-19 diagnoses were higher among persons living with dementia (PLWD) than those without dementia. Conditional on COVID-19 in the 2020 cohort, White PLWD were at higher risk of hospitalization compared to White persons without dementia (aOR 1.31, 95% CI: 1.26-1.36) and marginal for Black PLWD (aOR 1.10, 95% CI: 1.01-1.20), no significant differences were found within other racial/ethnic groups. PLWD were 1.8 times (aOR 1.78, 95% CI: 1.72-1.84) more likely to die within 30&#x2009;days of COVID-19 on average. Within racial/ethnic groups, the estimate for White PLWD, compared with White persons without dementia, was highest (aOR 2.01, 95% CI: 1.92-2.10), followed by Black PLWD (aOR 1.55, 95% CI: 1.41-1.70), and smallest among Hispanic PLWD (aOR 1.37, 95% CI: 1.24-1.50). PLWD hospitalized with COVID-19 were 1.6 times (aOR 1.59, 95% CI: 1.52-1.67) more likely to die within 30&#x2009;days than similar persons without dementia. Estimates from the 2021 cohort, when vaccines were available to older persons, were similar to those in 2020.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Community-dwelling PLWD experienced worse outcomes after a COVID-19 diagnosis than their counterparts without dementia. Results demonstrating higher mortality, but not hospitalization rates, for all races/ethnicities except White PLWD suggest there may have been differential care/treatment that point to potential health care system inequities that persisted into 2021. Understanding the mechanisms underlying these differences may improve ongoing care for community-dwelling PLWD.</AbstractText><CopyrightInformation>&#xa9; 2023 The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thunell</LastName><ForeName>Johanna A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-3361-4933</Identifier><AffiliationInfo><Affiliation>Price School of Public Policy, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferido</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zissimopoulos</LastName><ForeName>Julie M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Price School of Public Policy, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG055401</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24AG045061</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">disparities</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637869</ArticleId><ArticleId IdType="doi">10.1111/jgs.18230</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>CDC updates, expands list of people at risk of severe COVID-19 illness [press release]. June 25, 2020. 2020.</Citation></Reference><Reference><Citation>Areosa Sastre A, Vernooij RW, Gonz&#xe1;lez-Cola&#xe7;o Harmand M, Mart&#xed;nez G. Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6(6):CD003804.</Citation></Reference><Reference><Citation>Bunn F, Burn A-M, Goodman C, et al. Comorbidity and dementia: a scoping review of the literature. BMC Med. 2014;12(1):1-15.</Citation></Reference><Reference><Citation>Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer's disease and related dementias. Am J Geriatr Psychiatry. 2020;28(7):712-721.</Citation></Reference><Reference><Citation>Kuo C-L, Pilling LC, Atkins JL, et al. APOE e4 genotype predicts severe COVID-19 in the UK biobank community cohort. J Gerontol Ser A. 2020;75(11):2231-2232.</Citation></Reference><Reference><Citation>Tousi B. Dementia Care in the Time of COVID-19 pandemic. J Alzheimers Dis. 2020;76(2):475-479.</Citation></Reference><Reference><Citation>Mok VC, Pendlebury S, Wong A, et al. Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020;16(11):1571-1581.</Citation></Reference><Reference><Citation>Atkins JL, Masoli JA, Delgado J, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK biobank community cohort. J Gerontol Ser A. 2020;75(11):2224-2230.</Citation></Reference><Reference><Citation>Wang Q, Davis PB, Gurney ME, Xu R. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021;17(8):1297-1306.</Citation></Reference><Reference><Citation>Tahira AC, Verjovski-Almeida S, Ferreira STJAs, Dementia. Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients. 2021.</Citation></Reference><Reference><Citation>Hariyanto TI, Putri C, Arisa J, Situmeang RFV, Kurniawan A. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2021;93:104299.</Citation></Reference><Reference><Citation>Zuin M, Guasti P, Roncon L, Cervellati C, Zuliani G. Dementia and the risk of death in elderly patients with COVID-19 infection: systematic review and meta-analysis. Int J Geriatr Psychiatry. 2021;36(5):697-703.</Citation></Reference><Reference><Citation>Saragih ID, Saragih IS, Batubara SO, Lin C-J. Dementia as a mortality predictor among older adults with COVID-19: a systematic review and meta-analysis of observational study. Geriatr Nurs. 2021;42(5):1230-9.</Citation></Reference><Reference><Citation>Liu N, Sun J, Wang X, Zhao M, Huang Q, Li H. The impact of dementia on the clinical outcome of COVID-19: a systematic review and meta-analysis. J Alzheimers Dis. 2020;78(4):1775-1782.</Citation></Reference><Reference><Citation>Chang M-H, Moonesinghe R, Truman BI. COVID-19 hospitalization by race and ethnicity: association with chronic conditions among Medicare beneficiaries, January 1-September 30. J Racial Ethn Health Disparities. 2020;2021:1-10.</Citation></Reference><Reference><Citation>Izurieta HS, Graham DJ, Jiao Y, et al. Natural history of coronavirus disease 2019: risk factors for hospitalizations and deaths among&gt;&#x2009;26 million US Medicare beneficiaries. J Infect Dis. 2021;223(6):945-956.</Citation></Reference><Reference><Citation>Kim J, Blaum C, Ferris R, et al. Factors associated with hospital admission and severe outcomes for older patients with COVID-19. J Am Geriatr Soc. 2022;70:1906-1917.</Citation></Reference><Reference><Citation>Gilstrap L, Zhou W, Alsan M, Nanda A, Skinner JS. Trends in mortality rates among Medicare enrollees with Alzheimer disease and related dementias before and during the early phase of the COVID-19 pandemic. JAMA Neurol. 2022;79:342-348.</Citation></Reference><Reference><Citation>Faes C, Abrams S, Van Beckhoven D, et al. Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients. Int J Environ Res Public Health. 2020;17(20):7560.</Citation></Reference><Reference><Citation>Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis. 2020;26(6):1339-1441.</Citation></Reference><Reference><Citation>Thunell J, Ferido P, Zissimopoulos J. Measuring Alzheimer's disease and other dementias in diverse populations using medicare claims data. J Alzheimers Dis. 2019;72(1):29-33.</Citation></Reference><Reference><Citation>Chou SH-Y, Beghi E, Helbok R, et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19-a report for the GCS-NeuroCOVID consortium and the ENERGY consortium. JAMA Netw Open. 2021;4(5):e2112131.</Citation></Reference><Reference><Citation>Liu Y-H, Chen Y, Wang Q-H, et al. One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol. 2022;79(5):509-517.</Citation></Reference><Reference><Citation>Chen Y, Tysinger B, Crimmins E, Zissimopoulos JM. Analysis of dementia in the US population using Medicare claims: insights from linked survey and administrative claims data. Alzheimer's Dementia Trans Res Clin Interventions. 2019;5:197-207.</Citation></Reference><Reference><Citation>Centers for Medicare and Medicaid Services, Services M. Assessing the completeness of Medicare claims data for measuring COVID-19 vaccine administration. https://www.cms.gov/files/document/assessing-completeness-medicare-claims-data-measuring-covid-19-vaccine-administration.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637859</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-5548</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Diabetes care</Title><ISOAbbreviation>Diabetes Care</ISOAbbreviation></Journal><ArticleTitle>Incidence, Severity, and Presentation of Type 2 Diabetes in Youth During the First and Second Year of the COVID-19 Pandemic.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dc221702</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2337/dc22-1702</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the evolving impact of the coronavirus disease 2019 pandemic on the incidence and presentation of new-onset pediatric type 2 diabetes.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">Retrospective medical record review of youth with new-onset type 2 diabetes comparing the prepandemic period (1 January 2017-29 February 2020) with the first (1 March 2020-31 December 2020) and second pandemic year (1 January 2021-31 December 2021).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The annualized incidence of type 2 diabetes increased nearly threefold during the pandemic versus prior, with a 61% increase in the 2nd versus 1st year. BMI increased during the pandemic versus prior (129% of 95th percentile vs. 141%, P = 0.02). In the 1st year, patients were younger (12.9 years vs. 14.8, P &lt; 0.001), with higher incidence of diabetic ketoacidosis and/or hyperglycemic hyperosmolar syndrome (20% vs. 3.5%, P = 0.02) versus prior.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Providers should be aware of the escalating incidence of youth-onset type 2 diabetes to avoid delays in diagnosis and inform educational programs to combat the continued impact of the pandemic on health outcomes.</AbstractText><CopyrightInformation>&#xa9; 2023 by the American Diabetes Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sasidharan Pillai</LastName><ForeName>Sabitha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0391-3759</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Has</LastName><ForeName>Phinnara</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Lifespan Biostatistics, Epidemiology and Research Design, Rhode Island Hospital, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintos</LastName><ForeName>Jose Bernardo</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano Gonzalez</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasper</LastName><ForeName>Vania L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topor</LastName><ForeName>Lisa Swartz</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-1219-9921</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fredette</LastName><ForeName>Meghan E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-6674-7447</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Care</MedlineTA><NlmUniqueID>7805975</NlmUniqueID><ISSNLinking>0149-5992</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637859</ArticleId><ArticleId IdType="doi">10.2337/dc22-1702</ArticleId><ArticleId IdType="pii">148298</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637858</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3669</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Telemedicine journal and e-health : the official journal of the American Telemedicine Association</Title><ISOAbbreviation>Telemed J E Health</ISOAbbreviation></Journal><ArticleTitle>Telemedicine Has a Social Impact: An Italian National Study for the Evaluation of the Cost-Opportunity for Patients and Caregivers and the Measurement of Carbon Emission Savings.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1089/tmj.2022.0333</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> <i>Owing to COVID-19, all stakeholders have recognized the advantages of telehealth and they were available for its permanent implementation, both from the normative and economic point of view. It is, therefore, necessary to understand what were the real benefits created in society through telehealth.</i> <b><i>Objective:</i></b> <i>Develop a method to identify a social impact of telemedicine in Italy, considering the reduction on the patient moves with a consequent travel cost, time (opportunity costs), and carbon emission savings.</i> <b><i>Methods:</i></b> <i>Since March 2020, we have conducted a quality improvement study in 17 centers, collecting sociodemographic variables. To assess the social impact, we transform the data into outcome measures. The protocol used "Telemedicina Subito" allows the rapid implementation of telemedicine, using operating manual, structured according Health Technology Assessment approach.</i> <b><i>Results:</i></b> <i>We collected data related to 2,091 televisits, analyzing three different perspectives. First, one patient with a televisit had a saving equal to the median of EUR 97.16 (interquartile range [IQR]: 64.29-159.69), USD 113.88; considering that the median cost for the visit in presence was EUR 105.91 (</i>p<i>-value &lt;0.05) and after the use of telehealth had a median of EUR 0 (mean: EUR 14.70;</i> p<i>-value &lt;0.05). Second, informal caregivers have a median savings of EUR 65.06 (IQR: 55.52-89.21), USD 76.26. Finally, for one single telemedicine visits we can contribute with a median carbon emission savings of &#x223c;13&#x2009;kg (IQR: 6-24).</i> <b><i>Conclusions:</i></b> <i>The evaluation of the social impact on telemedicine facilitated the creation of an important framework for decision-makers.</i></AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papavero</LastName><ForeName>Sara Consilia</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fracasso</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramaglia</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4359-9415</Identifier><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicchetti</LastName><ForeName>Americo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Belvis</LastName><ForeName>Antonio Giulio</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Hygiene Section, Department of Life Sciences and Public Health, Catholic University of Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrara</LastName><ForeName>Fabrizio Massimo</ForeName><Initials>FM</Initials><Identifier Source="ORCID">0000-0002-8596-7346</Identifier><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Telemed J E Health</MedlineTA><NlmUniqueID>100959949</NlmUniqueID><ISSNLinking>1530-5627</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">carbon emission savings</Keyword><Keyword MajorTopicYN="N">caregiver</Keyword><Keyword MajorTopicYN="N">cost-opportunity</Keyword><Keyword MajorTopicYN="N">social impact</Keyword><Keyword MajorTopicYN="N">telemedicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637858</ArticleId><ArticleId IdType="doi">10.1089/tmj.2022.0333</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637857</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3669</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Telemedicine journal and e-health : the official journal of the American Telemedicine Association</Title><ISOAbbreviation>Telemed J E Health</ISOAbbreviation></Journal><ArticleTitle>Disparities in Use of Virtual Primary Care During the Early COVID-19 Pandemic.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1089/tmj.2022.0499</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> <i>The COVID-19 pandemic increased the use of virtual health care. However, certain factors may disparately affect some patients' utilization of virtual care. Associations between age, racial categories (White or Black), and socioeconomic disadvantage were evaluated during the early COVID-19 pandemic.</i> <b><i>Methods:</i></b> <i>This cross-sectional retrospective study included adult patients with virtual or in-person primary care encounters at a large, midwestern hospital system with widespread urban and suburban offices between March 1, 2020, and June 30, 2020. Virtual visits included synchronous video and telephone visits and asynchronous patient portal E-visits. Chi-squared tests and multivariable logistic analysis assessed the associations between ages and racial categories, and area deprivation index with the use of virtual versus in-person primary care.</i> <b><i>Results:</i></b> <i>Of 72,153 patient encounters, 43.0% were virtual visits, 54.6% were White patients, and 45.4% were Black. Across equivalent age ranges, black patients were slightly less likely to utilize virtual care than similarly aged White patients, but not consistently across virtual modalities. Women were more likely to use virtual care across all modalities, and individuals &gt;65 years were more likely to use telephone visits and less likely to use video and E-visits, regardless of race. Patients residing in areas with the greatest socioeconomic advantage were more likely to utilize video and E-visits.</i> <b><i>Conclusions:</i></b> <i>Differential patterns of utilization emerged across racial categories and age ranges, suggesting that racial disparities are exacerbated depending upon patient age and mode of utilization.</i></AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cherabuddi</LastName><ForeName>Medha R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-5715-4121</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidemann</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0512-2202</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwinn</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0707-4956</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White-Perkins</LastName><ForeName>Denise</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1868-2161</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willens</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4565-0915</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Anupama</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1896-5954</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Ed</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3546-3828</Identifier><AffiliationInfo><Affiliation>Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jesse</LastName><ForeName>Michelle T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0003-0847-0368</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transplant Institute, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Telemed J E Health</MedlineTA><NlmUniqueID>100959949</NlmUniqueID><ISSNLinking>1530-5627</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">disparities</Keyword><Keyword MajorTopicYN="N">primary care</Keyword><Keyword MajorTopicYN="N">telehealth</Keyword><Keyword MajorTopicYN="N">telemedicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637857</ArticleId><ArticleId IdType="doi">10.1089/tmj.2022.0499</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637854</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-843X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of women's health (2002)</Title><ISOAbbreviation>J Womens Health (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Women Authorship Trends in the Highest-Impact Anesthesiology Journals from 2005 to 2021.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1089/jwh.2022.0532</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> Although women and men have matriculated into medical schools in similar proportions since the 1980s, recent data indicate that anesthesiology is lagging in gender equity, especially in academic leadership roles.<sup>1,2</sup> As promotion in academic medicine is strongly influenced by publications, understanding whether a lack of women authorship is contributing to this gender gap is crucial.<sup>3,4</sup> This article aims to assess how woman authorship trends have changed in the last 16 years, including during the COVID-19 pandemic. <b><i>Methods:</i></b> The five highest impact journals in anesthesia were identified as <i>Journal of Clinical Anesthesia, British Journal of Anaesthesia</i>, <i>Anesthesiology</i>, <i>PAIN</i>, and <i>Regional Anesthesia &amp; Pain Medicine</i>. Number of total authors, including women, men, and unknown gender authors as well as incidence of woman first and/or last author, was documented from articles published in 2005, 2010, 2015, 2020, and 2021. <b><i>Results:</i></b> This analysis shows that women are gaining representation in anesthesia publications. Overall, there was a statistically significant increase in the total number of women authors and women first and last authorship. However, as of 2021, women still only represented &#x223c;40% of total and first authors and &#x223c;24% of last authors. In addition, increase in first/last woman authorship was not present in all journals when stratified. <b><i>Conclusion:</i></b> These journal differences may suggest the editorial evaluation process as a potential source of gender bias. There was a statistically significant relationship between women senior authors and articles with 50% or more women authors, indicating that woman mentorship is contributing to closing equity gap. These data present a starting point for further investigations into gender disparities within anesthesia to continue the forward progression for women in academic medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keim</LastName><ForeName>Audrey A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Alix School of Medicine, Scottsdale, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelkey</LastName><ForeName>Melissa N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Alix School of Medicine, Scottsdale, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broadfoot</LastName><ForeName>Jourdan E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0003-1479-4828</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folley</LastName><ForeName>Tarrah A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>Molly B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>Jillian A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strand</LastName><ForeName>Natalie H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misra</LastName><ForeName>Lopa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Womens Health (Larchmt)</MedlineTA><NlmUniqueID>101159262</NlmUniqueID><ISSNLinking>1540-9996</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anesthesiology</Keyword><Keyword MajorTopicYN="N">authorship</Keyword><Keyword MajorTopicYN="N">gender equity</Keyword><Keyword MajorTopicYN="N">mentorship</Keyword><Keyword MajorTopicYN="N">women in medicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637854</ArticleId><ArticleId IdType="doi">10.1089/jwh.2022.0532</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637836</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2379-3961</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>WMJ : official publication of the State Medical Society of Wisconsin</Title><ISOAbbreviation>WMJ</ISOAbbreviation></Journal><ArticleTitle>Increased Alcohol-Related Mortality in Wisconsin Pre-COVID: A Two-Decade Trend.</ArticleTitle><Pagination><StartPage>269</StartPage><EndPage>273</EndPage><MedlinePgn>269-273</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Alcohol-related mortality is increasing nationally, but state-specific trends still need to be explored. This paper reviews the patterning of alcohol-related deaths among Wisconsin residents in the 2 decades prior to the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data are from death certificates for state residents from 2000 through 2019. We used underlying cause of death codes (ICD-10) to classify deaths as 100% attributable to alcohol (ie, acute, chronic liver, and other chronic). Demographic characteristics were available for the most recent decedents (2015-2019). We assess trends in alcohol-related mortality and used chi-square tests to assess demographic differences compared to deaths from all other causes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The number of alcohol-related deaths more than doubled from 2000 through 2019 in Wisconsin, rising from 394 in 2000 to 857 in 2019. In the 5 most recent years (2015-2019), the populations with significantly higher rates of alcohol-related deaths included men, middle-aged adults, Black residents, and those of Hispanic descent. Education level also was significantly related to alcohol-attributable mortality, as those with the highest and lowest education levels were the least likely to die from this cause.</AbstractText><AbstractText Label="DISCUSSION/CONCLUSIONS" NlmCategory="CONCLUSIONS">Results of these analyses show that the number of deaths due to alcohol-related diseases has risen significantly since 2000, and this trend preceded the COVID-19 pandemic. These rising mortality rates deserve the attention of the medical and public health communities. Our findings show that, in recent years, Hispanic individuals, men, and middle-aged adults are at a higher risk for alcohol-related deaths. Stakeholders may wish to consider interventions targeted to these groups.</AbstractText><CopyrightInformation>Copyright&#xa9; Board of Regents of the University of Wisconsin System and The Medical College of Wisconsin, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Lynne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Wisconsin School of Journalism and Mass Communication, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bentley</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Bureau of Prevention Treatment and Recovery, Division of Care and Treatment Services, Wisconsin Department of Health Services, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imm</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Wisconsin Population Health Institute, Madison, Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bureau of Community Health Promotion, Wisconsin Department of Health Services, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creswell</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, pdcreswell@wisc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bureau of Environmental and Occupational Health, Wisconsin Department of Health Services, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>WMJ</MedlineTA><NlmUniqueID>9716054</NlmUniqueID><ISSNLinking>1098-1861</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637836</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637826</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Economic Burden of the 2020 COVID-19 Hospitalizations in Spain.</ArticleTitle><Pagination><StartPage>e2250960</StartPage><MedlinePgn>e2250960</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.50960</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#xc1;lvarez-Del R&#xed;o</LastName><ForeName>Blanca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-de Prada</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvaro-Meca</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Preventive Medicine and Public Health Department, Rey Juan Carlos University, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Fern&#xe1;ndez</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez</LastName><ForeName>F Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamayo</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez-Abej&#xf3;n</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Directorate, Castilla y Le&#xf3;n Health Council, Valladolid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This economic evaluation reports the total and per patient costs of inpatient care for COVID-19 in Spain in 2020.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637826</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.50960</ArticleId><ArticleId IdType="pii">2800407</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637818</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Inequities in Cancer Treatment Delay or Discontinuation Following SARS-CoV-2 Infection.</ArticleTitle><Pagination><StartPage>e2251165</StartPage><MedlinePgn>e2251165</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.51165</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">There is a disproportionately greater burden of COVID-19 among Hispanic and non-Hispanic Black individuals, who also experience poorer cancer outcomes. Understanding individual-level and area-level factors contributing to inequities at the intersection of COVID-19 and cancer is critical.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate associations of individual-level and area-level social determinants of health (SDOH) with delayed or discontinued cancer treatment following SARS-CoV-2 infection.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This retrospective, registry-based cohort study used data from 4768 patients receiving cancer care who had positive test results for SARS-CoV-2 and were enrolled in the American Society for Clinical Oncology COVID-19 Registry. Data were collected from April 1, 2020, to September 26, 2022.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="UNASSIGNED">Race and ethnicity, sex, age, and area-level SDOH based on zip codes of residence at the time of cancer diagnosis.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Delayed (&#x2265;14 days) or discontinued cancer treatment (any cancer treatment, surgery, pharmacotherapy, or radiotherapy) and time (in days) to restart pharmacotherapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 4768 patients (2756 women [57.8%]; 1558 [32.7%] aged &#x2265;70 years at diagnosis) were included in the analysis. There were 630 Hispanic (13.2%), 196 non-Hispanic Asian American or Pacific Islander (4.1%), 568 non-Hispanic Black (11.9%), and 3173 non-Hispanic White individuals (66.5%). Compared with non-Hispanic White individuals, Hispanic and non-Hispanic Black individuals were more likely to experience a delay of at least 14 days or discontinuation of any treatment and drug-based treatment; only estimates for non-Hispanic Black individuals were statistically significant, with correction for multiple comparisons (risk ratios [RRs], 1.35 [95% CI, 1.22-1.49] and 1.37 [95% CI, 1.23-1.52], respectively). Area-level SDOH (eg, geography, proportion of residents without health insurance or with only a high school education, lower median household income) were associated with delayed or discontinued treatment. In multivariable Cox proportinal hazards regression models, estimates suggested that Hispanic (hazard ratio [HR], 0.87 [95% CI, 0.71-1.05]), non-Hispanic Asian American or Pacific Islander (HR, 0.79 [95% CI, 0.46-1.35]), and non-Hispanic Black individuals (HR, 0.81 [95% CI, 0.67-0.97]) experienced longer delays to restarting pharmacotherapy compared with non-Hispanic White individuals.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">The findings of this cohort study suggest that race and ethnicity and area-level SDOH were associated with delayed or discontinued cancer treatment and longer delays to the restart of drug-based therapies following SARS-CoV-2 infection. Such treatment delays could exacerbate persistent cancer survival inequities in the United States.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Llanos</LastName><ForeName>Adana A M</ForeName><Initials>AAM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashrafi</LastName><ForeName>Adiba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Nabarun</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsui</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rutgers Cancer Institute of New Jersey, New Brunswick.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Angela J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Rutgers Cancer Institute of New Jersey, New Brunswick.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganesan</LastName><ForeName>Shridar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rutgers Cancer Institute of New Jersey, New Brunswick.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Pharmacology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckman</LastName><ForeName>Carolyn J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Rutgers Cancer Institute of New Jersey, New Brunswick.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637818</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.51165</ArticleId><ArticleId IdType="pii">2800399</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637810</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-2986</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2023</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of global health</Title><ISOAbbreviation>J Glob Health</ISOAbbreviation></Journal><ArticleTitle>Economic evaluation of COVID-19 vaccination: A systematic review.</ArticleTitle><Pagination><StartPage>06001</StartPage><MedlinePgn>06001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7189/jogh.13.06001</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Safe and effective vaccination is considered to be the most critical strategy to fight coronavirus disease 2019 (COVID-19), leading to individual and herd immunity protection. We aimed to systematically review the economic evaluation of COVID-19 vaccination globally.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a systematic search to identify relevant studies in two major databases (MEDLINE/PubMed and EBSCO) published until September 8, 2022. After deduplication, two researchers independently screened the study titles and abstracts according to pre-determined inclusion and exclusion criteria. The remaining full-text studies were assessed for eligibility. We assessed their quality of reporting using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist and summarized and narratively presented the results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified 25 studies that assessed the economic evaluation of COVID-19 vaccination worldwide by considering several input parameters, including vaccine cost, vaccine efficacy, utility value, and the size of the targeted population. All studies suggested that COVID-19 vaccination was a cost-effective or cost-saving intervention for mitigating coronavirus transmission and its effect in many countries within certain conditions. Most studies reported vaccine efficacy values ranging from 65% to 75%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Given the favorable cost-effectiveness profile of COVID-19 vaccines and disparities in affordability across countries, considering prioritization has become paramount. This review provides comprehensive insights into the economic evaluation of COVID-19 vaccination that will be useful to policymakers, particularly in highlighting preventive measures and preparedness plans for the next possible pandemic.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by the Journal of Global Health. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Utami</LastName><ForeName>Auliasari Meita</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rendrayani</LastName><ForeName>Farida</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Khoiry</LastName><ForeName>Qisty Aulia</ForeName><Initials>QA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noviyanti</LastName><ForeName>Dita</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwantika</LastName><ForeName>Auliya A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postma</LastName><ForeName>Maarten J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Economics, Econometrics &amp; Finance, University of Groningen, Faculty of Economics &amp; Business, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakiyah</LastName><ForeName>Neily</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Glob Health</MedlineTA><NlmUniqueID>101578780</NlmUniqueID><ISSNLinking>2047-2978</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and declare the following activities and relationships: MJP reports grants and honoraria from various pharmaceutical companies, also those involved in developing, producing, and marketing COVID-19 vaccines. Also, MJP is a member of the UK&#x2019;s Joint Committee of Vaccination &amp; Immunization. Other author reports no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637810</ArticleId><ArticleId IdType="doi">10.7189/jogh.13.06001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637803</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-2703</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of aerosol medicine and pulmonary drug delivery</Title><ISOAbbreviation>J Aerosol Med Pulm Drug Deliv</ISOAbbreviation></Journal><ArticleTitle>Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1089/jamp.2022.0062</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> Early in the coronavirus disease 2019 (COVID-19) pandemic, hydroxychloroquine (HCQ) drew substantial attention as a potential COVID-19 treatment based on its antiviral and immunomodulatory effects <i>in vitro</i>. However, HCQ showed a lack of efficacy <i>in vivo</i>, and different groups of researchers attributed this failure to the insufficient drug concentration in the lung following oral administration (HCQ is only available in the market in the tablet form). Delivering HCQ by inhalation represents a more efficient route of administration to increase HCQ exposure in the lungs while minimizing systemic toxicity. In this pilot study, the safety, tolerability, and pharmacokinetics of HCQ nebulizer solution were evaluated in healthy volunteers. <b><i>Methods:</i></b> Twelve healthy participants were included in this study and were administered 2&#x2009;mL of HCQ01 solution (equivalent to 25&#x2009;mg of HCQ sulfate) through Aerogen<sup>&#xae;</sup> Solo, a vibrating mesh nebulizer. Local tolerability and systemic safety were assessed by forced expiratory volume in the first and second electrocardiograms, clinical laboratory results (e.g., hematology, biochemistry, and urinalysis), vital signs, and physical examinations. Thirteen blood samples were collected to determine HCQ01 systemic exposure before and until 6 hours after inhalation. <b><i>Results:</i></b> The inhalation of HCQ01 was well tolerated in all participants. The mean value of <i>C</i><sub>max</sub> for the 12 participants was 9.66&#x2009;ng/mL. <i>T</i><sub>max</sub> occurred at around 4.8 minutes after inhalation and rapidly decreased thereafter. The reported systemic exposure was very low with a mean value of 5.28 (0.6-15.6) ng&#xb7;h/mL. <b><i>Conclusion:</i></b> The low systemic concentrations of HCQ01 of 9.66&#x2009;ng/mL reported by our study compared with 1&#x2009;&#x3bc;g/mL previously predicted after 200&#x2009;mg BID oral administration, and the safety and tolerability of HCQ01 administered as a single dose through nebulization, support the assessment of its efficacy, safety, and tolerability in further studies for the treatment of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hawari</LastName><ForeName>Feras</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Office of Minister of Health, Ministry of Health, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodin</LastName><ForeName>Yasmeen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cancer Control Office, King Hussein Cancer Center, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tayyem</LastName><ForeName>Rabab</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ACDIMA Biocenter, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najjar</LastName><ForeName>Samer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sana Pharmaceutical Industry, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakish</LastName><ForeName>Hanan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Amman Pharmaceutical Industries, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fara</LastName><ForeName>Mohammed Abu</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>ACDIMA Biocenter, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou'bi</LastName><ForeName>Abdullah Al</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>ACDIMA Biocenter, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idkaidek</LastName><ForeName>Nasir</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3115-4240</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy and Medical Sciences, The University of Petra, Amman, Jordan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Aerosol Med Pulm Drug Deliv</MedlineTA><NlmUniqueID>101475057</NlmUniqueID><ISSNLinking>1941-2711</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">inhalable hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">lung diseases</Keyword><Keyword MajorTopicYN="N">nebulizer</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">phase I study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637803</ArticleId><ArticleId IdType="doi">10.1089/jamp.2022.0062</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637742</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1970-9366</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Internal and emergency medicine</Title><ISOAbbreviation>Intern Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11739-022-03185-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colangeli</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8603-664X</Identifier><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. luca.colangeli.ptv@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit and Obesity Center, University Hospital Policlinico Tor Vergata, Rome, Italy. luca.colangeli.ptv@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aprile</LastName><ForeName>Gianna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carcone</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Adamo</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit and Obesity Center, University Hospital Policlinico Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medda</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Behavioural Sciences and Mental Health, Istituto Superiore Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbraccia</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit and Obesity Center, University Hospital Policlinico Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guglielmi</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit and Obesity Center, University Hospital Policlinico Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Intern Emerg Med</MedlineTA><NlmUniqueID>101263418</NlmUniqueID><ISSNLinking>1828-0447</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Internal Medicine</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword><Keyword MajorTopicYN="N">Variant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637742</ArticleId><ArticleId IdType="doi">10.1007/s11739-022-03185-5</ArticleId><ArticleId IdType="pii">10.1007/s11739-022-03185-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603&#x2013;2615</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403&#x2013;416</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J et al (2021) Safety and efficacy of single-dose ad26cov2s vaccine against covid-19. N Engl J Med 384(23):2187&#x2013;2201</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkle LM et al (2022) Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med 386(6):531&#x2013;543</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsin M, Mahmud S (2022) Omicron SARS-CoV-2 variant of concern: a review on its transmissibility, immune evasion, reinfection, and severity. Medicine 101(19):e29165</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000029165</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH (2022) Covid-19 vaccines - immunity, variants Boosters. N Engl J Med 387(11):1011&#x2013;1020</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2206573</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian D et al (2022) The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol 94(6):2376&#x2013;2383</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng HF et al (2022) Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med 28(5):1063&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01753-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Corradini E et al (2021) Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Intern Emerg Med 16(4):1005&#x2013;1015</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02742-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmi V et al (2022) Inflammation, underweight, malignancy and a marked catabolic state as predictors for worse outcomes in COVID-19 patients with moderate-to-severe disease admitted to internal medicine unit. PLoS One 17(5):e0268432</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenti MV et al (2022) Determinants of COVID-19-related mortality in an internal medicine setting. Intern Emerg Med 17(7):2169&#x2013;2173</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-022-03057-y</ArticleId></ArticleIdList></Reference><Reference><Citation>AIFA. Trattamenti utilizzabili nei pazienti COVID-19 nel setting ospedaliero. 2022 26/NOV/2022]; Available from: https://www.aifa.gov.it/documents/20142/1269602/SOC_ospedaliera_03_06.06.2022.pdf .</Citation></Reference><Reference><Citation>Razonable RR et al (2022) Real-world clinical outcomes of bebtelovimab and sotrovimab treatment of high-risk persons with coronavirus disease 2019 during the omicron epoch. Open Forum Infect Dis 9(10):411</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazanfar H et al (2022) Outcomes of monoclonal antibody infusion treatment during delta (B16172) and omicron (B11529) COVID 19 variant surges among vaccinated and unvaccinated patients. Health Serv Insights 15:11786329221127152</Citation></Reference><Reference><Citation>Ward IL et al (2022) Risk of covid-19 related deaths for SARS-CoV-2 omicron (B1.1.529) compared with delta (B.1.617.2): retrospective cohort study. Bmj. 378:e070695</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-070695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Roshani A, Klausner JD (2022) Duration of COVID-19 PCR positivity for Omicron vs earlier variants. J Clin Virol Plus 2(3):100085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcvp.2022.100085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637636</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Mortality in psoriatic arthritis patients, changes over time, and the impact of COVID-19: results from a multicenter Psoriatic Arthritis Registry (PsART-ID).</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-022-06492-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to assess the mortality of PsA before and during the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From the prospective, multicenter PsART-ID (Psoriatic Arthritis Registry-International Database), patients from Turkey were analyzed by linking the registry to the Turkish Cause of Death Registry. The outcome of interest was death from any cause, pre-pandemic (since the onset of registry-March 2014-March 2020), and during the pandemic (March 2020-May 2021). The crude mortality rate and standardized mortality ratio (SMR) were determined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 1216 PsA patients with a follow-up of 7500 patient-years. Overall, 46 deaths (26 males) were observed. In the pre-pandemic period, SMR for PsA vs the general population was 0.95 (0.61-1.49), being higher in males [1.56 (0.92-2.63)] than females [0.62 (0.33-1.17)]. The crude mortality rate in PsA doubled during the pandemic (pre-pandemic crude mortality rate: 5.07 vs 10.76 during the pandemic) with a higher increase in females (2.9 vs 8.72) than males (9.07 vs 14.73).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The mortality in PsA was found similar to the general population in the pre-pandemic era. The mortality rates in PsA doubled during the pandemic. Whether PsA patients have more risk of mortality than the general population due to COVID-19 needs further studies. Key Points &#x2022; Decrease in mortality in PsA might be expected with the more effective treatment options and better disease control. &#x2022; A crude mortality rate is comparable to the general population and not increased until the pandemic. &#x2022; Currently, there is a 2-fold increase in crude mortality rate possibly due to the COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erden</LastName><ForeName>Abdulsamet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Ministry of Health Ankara City Hospital, Ankara, 06800, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayan</LastName><ForeName>Gizem</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University Medical School, Sihhiye, Ankara, 06100, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilic</LastName><ForeName>Levent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University Medical School, Sihhiye, Ankara, 06100, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solmaz</LastName><ForeName>Dilek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakirci</LastName><ForeName>Sibel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya Training and Research Hospital, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimyon</LastName><ForeName>Gezmis</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Mustafa Kemal University, Antakya, Hatay, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nal</LastName><ForeName>Esen Kasapoglu</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Medeniyet University, Goztepe Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dogru</LastName><ForeName>Atalay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Suleyman Demirel University, Isparta, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayindir</LastName><ForeName>Ozun</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalkilic</LastName><ForeName>Ediz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Uludag University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zisler</LastName><ForeName>Cem</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akar</LastName><ForeName>Servet</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cetin</LastName><ForeName>G&#xf6;zde Yildirim</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarhan</LastName><ForeName>Emine Figen</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Mugla Sitki Kocman University, Mugla, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;&#xe7;&#xfc;ksahin</LastName><ForeName>Orhan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara Yildirim Beyazit University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omma</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonullu</LastName><ForeName>Emel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Sakarya University, Sakarya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Fatih</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ersozlu</LastName><ForeName>Emine Duygu</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Adana Numune Training and Research Hospital, Adana, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cinar</LastName><ForeName>Muhammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, G&#xfc;lhane Training and Research Hospital, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tufan</LastName><ForeName>Abdurrahman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pehlevan</LastName><ForeName>Seval</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Fatih University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmen</LastName><ForeName>Serpil Ergulu</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Konya Education and Research Hospital, Konya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>Sema</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Selcuk University, Konya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duruoz</LastName><ForeName>Tuncay</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Marmara University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasifoglu</LastName><ForeName>Timucin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University, Eskisehir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaz&#x131;s&#x131;z</LastName><ForeName>Veli</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology,, Akdeniz University, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksu</LastName><ForeName>Kenan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aydin</LastName><ForeName>Sibel Zehra</ForeName><Initials>SZ</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalyoncu</LastName><ForeName>Umut</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-7129-2109</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University Medical School, Sihhiye, Ankara, 06100, Turkey. umut.kalyoncu@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">Psoriatic arthritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637636</ArticleId><ArticleId IdType="doi">10.1007/s10067-022-06492-6</ArticleId><ArticleId IdType="pii">10.1007/s10067-022-06492-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gupta S, Syrimi Z, Hughes DM, Zhao SS (2021) Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 41:275&#x2013;284. https://doi.org/10.1007/s00296-020-04775-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04775-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman D (2007) Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 56:2708&#x2013;2714. https://doi.org/10.1002/art.22800</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22800</ArticleId></ArticleIdList></Reference><Reference><Citation>Bower H, Frisell T, Di Giuseppe D et al (2021) Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis 80:1086&#x2013;1093. https://doi.org/10.1136/annrheumdis-2021-219845</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-219845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyoncu U, Bayindir &#xd6;, Ferhat &#xd6;ks&#xfc;z M et al (2017) The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford) 56:279&#x2013;286. https://doi.org/10.1093/rheumatology/kew375</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakirci S, Ayan G, Gazel U, Tinazzi I, Solmaz D, Kasapoglu E, Kalyoncu U, Aydin SZ (2021) Patient characteristics and minimal disease activity in psoriatic arthritis: a transcontinental comparison. Clin Rheumatol 40:3169&#x2013;3174. https://doi.org/10.1007/s10067-021-05648-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05648-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF (2011) Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 63:1182&#x2013;1189. https://doi.org/10.1002/art.30277</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30277</ArticleId></ArticleIdList></Reference><Reference><Citation>Aron JM, J (2020) Transatlantic excess mortality comparisons in the pandemic. INET Oxford Working Paper No-18 https://ourworldindata.org/covid.excess.mortality . Accessed 9 Jan 2023</Citation></Reference><Reference><Citation>Morfeld P, Timmermann B, Gro&#xdf; JV, Lewis P, Cocco P, Erren TC (2021) COVID-19: heterogeneous excess mortality and &#x201c;burden of disease&#x201d; in Germany and Italy and their states and regions, January&#x2013;June 2020. Front Public Health 9:663259. https://doi.org/10.3389/fpubh.2021.663259</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.663259</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MMA, Khan MN, Mustagir MG, Rana J, Islam S, Kabir I (2020) Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: a systematic review and meta-analysis. J Glob Health 10:020503. https://doi.org/10.7189/jogh.10.020503</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.10.020503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637634</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Outcomes of Filipinos with inflammatory rheumatic diseases developing COVID-19 prior to vaccinations and new variants: a historical perspective.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06507-w</ELocationID><Abstract><AbstractText>We described the profile and outcome of Filipino patients with inflammatory rheumatic diseases (IRDs) who developed COVID-19 (IRD-C19) during the onset of the pandemic, prior to vaccinations and variants. We obtained de-identified data of Filipino patients with IRD-C19 from the Global Rheumatology Alliance registry from March 2020 to August 2021. Descriptive statistics and multivariate analyses were applied. Registered were 164 patients (mean age 44&#xa0;years; 70% female). The most common IRDs were systemic lupus erythematosus (SLE, 41.4%), rheumatoid arthritis (RA, 15.2%), and gout (14.6%). Majority were receiving conventional DMARDs (59.1%) and/or glucocorticoid therapy (GC, 51.2%). Half (58.5%) were hospitalized, with risk higher in active IRD (OR 3.7), heart disease&#xa0;(8.52), and hypertension&#xa0;(8.73); and lower in SLE patients (0.15). Among hospitalized patients, 76% needed supplemental oxygen. Heart disease (6.28), hypertension (7.6), and moderate-to-high IRD activity (3.37) were associated with higher odds of requiring oxygen supplementation. Hypertension was associated with mechanical ventilation (8.23).&#xa0;Twenty-four (15%) patients died, with odds lower if on prednisone&#x2009;&#x2265;&#x2009;10&#xa0;mg/day (0.17) and with other autoimmune IRDs aside from SLE and RA (0.05). Among patients with IRD-C19 prior to vaccinations and variants, higher disease activity, hypertension, and heart disease were associated with poorer outcomes. Prednisone&#x2009;&#x2265;&#x2009;10&#xa0;mg/day was associated with lower odds of death. This study provides valuable historical information, emphasizing the need for continued data collection to clarify COVID-19's impact.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zamora-Abrahan</LastName><ForeName>Geraldine Tong</ForeName><Initials>GT</Initials><Identifier Source="ORCID">0000-0003-3125-9114</Identifier><AffiliationInfo><Affiliation>University of the Philippines Manila, Manila, Philippines. gtzamora@up.edu.ph.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salido</LastName><ForeName>Evelyn Osio</ForeName><Initials>EO</Initials><Identifier Source="ORCID">0000-0003-1653-2143</Identifier><AffiliationInfo><Affiliation>University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asian Hospital and Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichauco</LastName><ForeName>Juan Javier Tayengco</ForeName><Initials>JJT</Initials><AffiliationInfo><Affiliation>St. Luke's Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez-Rubio</LastName><ForeName>Anna Kristina Manahan</ForeName><Initials>AKM</Initials><Identifier Source="ORCID">0000-0003-1322-9827</Identifier><AffiliationInfo><Affiliation>Makati Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Go</LastName><ForeName>Ivy Catherine Talavera</ForeName><Initials>ICT</Initials><AffiliationInfo><Affiliation>Medical Center Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortez</LastName><ForeName>Karen Joy Casta&#xf1;eda</ForeName><Initials>KJC</Initials><AffiliationInfo><Affiliation>Baguio General Hospital and Medical Center, Baguio City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suilan</LastName><ForeName>Katrina Elys Arada</ForeName><Initials>KEA</Initials><AffiliationInfo><Affiliation>University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villo</LastName><ForeName>Jimmy Gene Bobot</ForeName><Initials>JGB</Initials><AffiliationInfo><Affiliation>East Avenue Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Rosario</LastName><ForeName>Adora Gatlabayan</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>East Avenue Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 immunopathology</Keyword><Keyword MajorTopicYN="N">Filipino patients</Keyword><Keyword MajorTopicYN="N">Global Rheumatology Alliance</Keyword><Keyword MajorTopicYN="N">Registry</Keyword><Keyword MajorTopicYN="N">Rheumatic disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637634</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06507-w</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06507-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grainger R, Machado PM, Robinson PC (2021) Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes. Clin Rheumatol 35:101657. https://doi.org/10.1016/j.berh.2020.101657</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2020.101657</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859&#x2013;866. https://doi.org/10.1136/annrheumdis-2020-217871</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R (2021) Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data. Autoimmun Rev 20:102778. https://doi.org/10.1016/j.autrev.2021.102778</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102778</ArticleId></ArticleIdList></Reference><Reference><Citation>Salido EO, Manapat-Reyes H, Dans L (2009) Serum uric acid and its relationship with demographic characteristics among Filipino adults 20 years old and above: results from the NNHeS 2003. Phil J Intern Med 46:273&#x2013;278. https://doi.org/10.3860/pjim.v46i6.888</Citation><ArticleIdList><ArticleId IdType="doi">10.3860/pjim.v46i6.888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigley RD, Manahan L, Muirden KD (1991) Rheumatic disease in a Philippine village II: a WHO-APLAR COPCORD study, phase II and III. Rheumatol Int 11:152&#x2013;161. https://doi.org/10.1007/BF00332554</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00332554</ArticleId></ArticleIdList></Reference><Reference><Citation>Dans LS, Salido EO, Penserga EG, Navarra SV (2006) National Nutrition and Health Survey (NNHeS): prevalence of rheumatic diseases among adult Filipinos. Phil J Intern Med 44:297&#x2013;303</Citation></Reference><Reference><Citation>Salido EO, Tee CA, Reyes PWC, Reyes BHM, Zamora GT, Tee ML (2021) Self-reported symptoms in a cohort of rheumatoid arthritis and lupus erythematosus during the COVID-19 quarantine period. The Open Rheumatol J 15:16&#x2013;23. https://doi.org/10.2174/1874312902115010016</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874312902115010016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonf&#xe1; E, Gossec L, Isenberg DA, Li Z, Raychaudhuri S (2021) Viewpoint: How COVID-19 is changing rheumatology clinical practice? Nat Rev Rheumatol 17:11&#x2013;15. https://doi.org/10.1038/s41584-020-00527-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-00527-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497&#x2013;506. https://doi.org/10.1016/S0140-6736(20)30183-5pmid:31986264</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5pmid:31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippine Society for Microbiology and Infectious Diseases. (n.d.) Interim Guidelines on the Clinical Management of Adult Patients with Suspected or Confirmed Covid-19 Infection. https://pcp.org.ph/index.php/interim-guidelines . Accessed September 24, 2021</Citation></Reference><Reference><Citation>Liu X, Zhang R, He G (2020) Hematological findings in coronavirus disease 2019: indications of progression of disease. Ann Hematol 99:1421&#x2013;1428. https://doi.org/10.1007/s00277-020-04103-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-020-04103-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G et al (2020) Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med 80:1&#x2013;11. https://doi.org/10.1016/j.ejim.2020.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D et al (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76:428&#x2013;455. https://doi.org/10.1111/all.14657</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239&#x2013;1242. https://doi.org/10.1001/jama.2020.2648</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId></ArticleIdList></Reference><Reference><Citation>Topless RK, Phipps-Green A, Leask M, Dalbeth N, Stamp LK, Robinson PC et al (2021) Gout, rheumatoid arthritis and the risk of death from COVID-19: an analysis of the UK Biobank. Open Rheumatol 3:333&#x2013;340. https://doi.org/10.1002/acr2.11252</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Zhong J, Cai S, Dong L, Li C, Hou X et al (2021) COVID-19 infection in patients with connective tissue disease: a multicity study in Hubei province, China. MedComm 2:82&#x2013;90. https://doi.org/10.1002/mco2.56</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.56</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen KM, Bates BA, Rashidi ES, Olex AL, Mannon RB, Patel RC et al (2022) National COVID Cohort Collaborative Consortium. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet 4:e33&#x2013;e41. https://doi.org/10.1016/S2665-9913(21)00325-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00325-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee CA, Salido EO, Reyes PWC, Ho RC, Tee ML (2020) Psychological state and associated factors during the 2019 coronavirus disease (COVID-19) pandemic among Filipinos with rheumatoid arthritis or systemic lupus erythematosus. Open Access Rheumatol 12:215&#x2013;222. https://doi.org/10.2147/OARRR.S269889</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S269889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637614</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2196-8837</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of racial and ethnic health disparities</Title><ISOAbbreviation>J Racial Ethn Health Disparities</ISOAbbreviation></Journal><ArticleTitle>Racial Disparities in the Clinical Prognosis of Gastrointestinal Cancer Patients with COVID-19: a Retrospective Study in UC CORDS.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40615-023-01512-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cancer patients are highly vulnerable to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Few studies have examined racial disparities of clinical prognosis among gastrointestinal (GI) cancer patients with COVID-19, especially after the approval of COVID-19 vaccines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective study based on the University of California COVID Research Data Set (UC CORDS). Patients aged&#x2009;&#x2265;&#x2009;18 with GI cancer as well as SARS-CoV-2 infection between March 10, 2020, and May 8, 2022, were included. We examined racial disparities using multivariable logistic regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 1054 GI cancer cases included, 117 (11.1%) patients were Asian and Pacific Islander, 51 (4.8%) were Black patients, 377 (35.8%) were Hispanic patients, 403 (38.2%) were White patients, and 106 (10.1%) belonged to other or unknown races. Fully adjusted logistic models revealed a significantly increased risk of COVID-19-related hospitalization or emergency room visits among the Black (OR&#x2009;=&#x2009;2.26, 95% CI&#x2009;=&#x2009;1.08-4.70), the Hispanic (OR&#x2009;=&#x2009;2.24, 95% CI&#x2009;=&#x2009;1.48-3.39), and the patients of other or unknown races (OR&#x2009;=&#x2009;1.80, 95% CI&#x2009;=&#x2009;1.00-3.26) compared with the White patients. No significant racial disparities in 30-day all-cause mortality and mechanical ventilation rate were found. Vaccination, age, cancer type, recent cancer diagnoses in UC CORDS, metastatic cancer or secondary malignant neoplasm, and Charlson comorbidity index score were associated with the prognosis of GI cancer patients with COVID-19.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GI cancer patients belonging to racial minorities experience worse COVID-19 outcomes. Vaccination status is a crucial factor associated with GI cancer patients' prognosis among different race/ethnicity groups. Targeted communication in the context of cancer is needed to encourage vaccination uptake in this vulnerable population.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Bingya</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Population Health and Disease Prevention, Program in Public Health, Susan and Henry Samueli College of Health Sciences, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yunxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Population Health and Disease Prevention, Program in Public Health, Susan and Henry Samueli College of Health Sciences, University of California, Irvine, CA, USA. Yunxia.lu@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Racial Ethn Health Disparities</MedlineTA><NlmUniqueID>101628476</NlmUniqueID><ISSNLinking>2196-8837</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Gastrointestinal cancer</Keyword><Keyword MajorTopicYN="N">Racial groups</Keyword><Keyword MajorTopicYN="N">SARS-COV-2</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637614</ArticleId><ArticleId IdType="doi">10.1007/s40615-023-01512-w</ArticleId><ArticleId IdType="pii">10.1007/s40615-023-01512-w</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157&#x2013;60. https://doi.org/10.23750/abm.v91i1.9397 .</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i1.9397</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17(3):519&#x2013;27. https://doi.org/10.20892/j.issn.2095-3941.2020.0289 .</Citation><ArticleIdList><ArticleId IdType="doi">10.20892/j.issn.2095-3941.2020.0289</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillmore NR, La J, Szalat RE, et al. Prevalence and outcome of COVID-19 infection in cancer patients: a National Veterans Affairs study. J Natl Cancer Inst. 2021;113(6):691&#x2013;8. https://doi.org/10.1093/jnci/djaa159 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djaa159</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell B, Moss C, Papa S, et al. Factors affecting COVID-19 outcomes in cancer patients: a first report from Guy&#x2019;s Cancer Center in London. Front Oncol. 2020;10:1279. https://doi.org/10.3389/fonc.2020.01279 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.01279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021;7(2):220&#x2013;7. https://doi.org/10.1001/jamaoncol.2020.6178 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2020.6178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J, Reid SA, French B, et al. Racial disparities in COVID-19 outcomes among Black and White patients wit h cancer. JAMA Netw Open. 2022;5(3):e224304. https://doi.org/10.1001/jamanetworkopen.2022.4304 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.4304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kathuria-Prakash N, Antrim L, Hornstein N, et al. Factors associated with hospitalization among breast cancer patients with COVID-19: a diverse multi-center Los Angeles cohort study. Clin Breast Cancer. 2022;22(4):e558&#x2013;66. https://doi.org/10.1016/j.clbc.2021.12.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clbc.2021.12.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara OD, Smith MJ, Wang Y, et al. Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy. Cancer. 2021;127(7):1057&#x2013;67. https://doi.org/10.1002/cncr.33335 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33335</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox TA, Troy-Barnes E, Kirkwood AA, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol. 2020;191(2):194&#x2013;206. https://doi.org/10.1111/bjh.17027 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AL, Tucker MD, Bakouny Z, et al. Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19. JAMA Netw Open. 2021;4(11):e2134330. https://doi.org/10.1001/jamanetworkopen.2021.34330 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.34330</ArticleId></ArticleIdList></Reference><Reference><Citation>California Population Estimates. United States Census Bureau. Updated July 1, 2021. Accessed July 9, 2022. https://www.census.gov/quickfacts/fact/table/CA/PST045221 .</Citation></Reference><Reference><Citation>Ashktorab H, Kupfer SS, Brim H, Carethers JM. Racial disparity in gastrointestinal cancer risk. Gastroenterology. 2017;153(4):910&#x2013;23. https://doi.org/10.1053/j.gastro.2017.08.018 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.08.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller C, Ihionkhan E, Stoffel EM, Kupfer SS. Disparities in Early-Onset Colorectal Cancer. Cells. 2021;10(5):1018. https://doi.org/10.3390/cells10051018.</Citation></Reference><Reference><Citation>Salvatore M, Jeon J, Meza R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992&#x2013;2016. Cancer Causes Control. 2019;30(12):1377&#x2013;88. https://doi.org/10.1007/s10552-019-01237-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10552-019-01237-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer J Clin. 2022;72(1):7&#x2013;33. https://doi.org/10.3322/caac.21708 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: first approval. Drugs. 2021;81(4):495&#x2013;501. https://doi.org/10.1007/s40265-021-01480-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01480-7</ArticleId></ArticleIdList></Reference><Reference><Citation>University of California Health creates centralized data set to accelerate COVID-19 research. Univ California Health. Published July 15, 2020. Accessed January 23, 2022. https://www.universityofcalifornia.edu/press-room/university-california-health-creates-centralized-data-set-accelerate-covid-19-research .</Citation></Reference><Reference><Citation>Kim Y, Tian Y, Yang J, et al. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis. Sci Rep. 2020;10(1):11115. https://doi.org/10.1038/s41598-020-68037-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-68037-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188&#x2013;97.</Citation></Reference><Reference><Citation>Variants. CALIFORNIA ALL. Updated May 24, 2022. Accessed April 25, 2022. https://covid19.ca.gov/variants/ .</Citation></Reference><Reference><Citation>Curran T, Sun Z, Gerry B, et al. Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Med. 2021;10(5):1805&#x2013;14. https://doi.org/10.1002/cam4.3753 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3753</ArticleId></ArticleIdList></Reference><Reference><Citation>Simopoulos AP. Genetic variation, diet, inflammation, and the risk for COVID-19. Lifestyle Genom. 2021;14(2):37&#x2013;42. https://doi.org/10.1159/000513886 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000513886</ArticleId></ArticleIdList></Reference><Reference><Citation>Paremoer L, Nandi S, Serag H, Baum F. Covid-19 pandemic and the social determinants of health. BMJ. 2021;372:n129. Published 2021 Jan 28. https://doi.org/10.1136/bmj.n129.</Citation></Reference><Reference><Citation>Schmidt AL, Bakouny Z, Bhalla S, et al. Cancer care disparities during the COVID-19 pandemic: COVID-19 and cancer outcomes study. Cancer Cell. 2020;38(6):769&#x2013;70. https://doi.org/10.1016/j.ccell.2020.10.023 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.10.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis LK, Hsu CH, Arrington AK. Reduction in standard cancer screening in 2020 throughout the U.S. Cancers (Basel). 2021;13(23):5918. https://doi.org/10.3390/cancers13235918.</Citation></Reference><Reference><Citation>Boulware LE. Race Disparities in the COVID-19 pandemic-solutions lie in policy, not biology. JAMA Netw Open. 2020;3(8):e2018696. Published 2020 Aug 3. https://doi.org/10.1001/jamanetworkopen.2020.18696.</Citation></Reference><Reference><Citation>Yearby R, Mohapatra S. Law, structural racism, and the COVID-19 pandemic. J Law Biosci. 2020;7(1):lsaa036. Published 2020 Jun 29. https://doi.org/10.1093/jlb/lsaa036.</Citation></Reference><Reference><Citation>Chowkwanyun M, Reed AL Jr. Racial health disparities and Covid-19 - caution and context. N Engl J Med. 2020;383(3):201&#x2013;3. https://doi.org/10.1056/NEJMp2012910 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2012910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yearby R. Reifying racism in the COVID-19 pandemic response. Am J Bioeth. 2021;21(3):75&#x2013;8. https://doi.org/10.1080/15265161.2020.1870773 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15265161.2020.1870773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon DH, Cadena J, Nguyen S, et al. COVID-19 outcomes in patients with cancer: findings from the University of California health system database. Cancer Med. 2022;11(11):2204&#x2013;15. https://doi.org/10.1002/cam4.4604 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.4604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833&#x2013;9. https://doi.org/10.1016/j.jiph.2020.07.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Klein SL, Garibaldi BT, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. https://doi.org/10.1016/j.arr.2020.101205 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101205</ArticleId></ArticleIdList></Reference><Reference><Citation>Raza HA, Sen P, Bhatti OA, Gupta L. Sex hormones, autoimmunity and gender disparity in COVID-19. Rheumatol Int. 2021;41(8):1375&#x2013;86. https://doi.org/10.1007/s00296-021-04873-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04873-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907&#x2013;18. https://doi.org/10.1016/S0140-6736(20)31187-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31187-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelo-Branco L, Tsourti Z, Gennatas S, et al. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE). ESMO Open. 2022;7(3):100499. https://doi.org/10.1016/j.esmoop.2022.100499 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esmoop.2022.100499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Kudo M. Impacts of COVID-19 on liver cancers: during and after the pandemic. Liver Cancer. 2020;9(5):491&#x2013;502. https://doi.org/10.1159/000510765 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000510765</ArticleId></ArticleIdList></Reference><Reference><Citation>Monin L, Laing AG, Mu&#xf1;oz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765&#x2013;78. https://doi.org/10.1016/S1470-2045(21)00213-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00213-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AL, Labaki C, Hsu CY, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2022;33(3):340&#x2013;6. https://doi.org/10.1016/j.annonc.2021.12.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Poghosyan H, Dinan MA, Tamamyan G, Nelson L, Jeon S. Racial and ethnic variation in COVID-19 vaccination uptake among Medicare beneficiaries with cancer history [published online ahead of print, 2022 Sep 23]. J Racial Ethn Health Disparities. 2022;1&#x2013;9. https://doi.org/10.1007/s40615-022-01415-2.</Citation></Reference><Reference><Citation>Coronavirus (COVID-19) Vaccinations. Our world in Data. Updated July 4, 2022. Accessed July 5, 2022. https://ourworldindata.org/covid-vaccinations?country=USA .</Citation></Reference><Reference><Citation>MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015;33(34):4161&#x2013;4. https://doi.org/10.1016/j.vaccine.2015.04.036 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.04.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen M, Bain N, Grech L, et al. COVID&#x2010;19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: a multicenter study. Asia-Pac J Clin Oncol. Published online January 18, 2022. https://doi.org/10.1111/ajco.13754.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637563</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1522-9602</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Bulletin of mathematical biology</Title><ISOAbbreviation>Bull Math Biol</ISOAbbreviation></Journal><ArticleTitle>Modeling and Global Sensitivity Analysis of Strategies to Mitigate Covid-19 Transmission on a Structured College Campus.</ArticleTitle><Pagination><StartPage>13</StartPage><MedlinePgn>13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11538-022-01107-2</ELocationID><Abstract><AbstractText>In response to the COVID-19 pandemic, many higher educational institutions moved their courses on-line in hopes of slowing disease spread. The advent of multiple highly-effective vaccines offers the promise of a return to "normal" in-person operations, but it is not clear if-or for how long-campuses should employ non-pharmaceutical interventions such as requiring masks or capping the size of in-person courses. In this study, we develop and fine-tune a model of COVID-19 spread to UC Merced's student and faculty population. We perform a global sensitivity analysis to consider how both pharmaceutical and non-pharmaceutical interventions impact disease spread. Our work reveals that vaccines alone may not be sufficient to eradicate disease dynamics and that significant contact with an infectious surrounding community will maintain infections on-campus. Our work provides a foundation for higher-education planning allowing campuses to balance the benefits of in-person instruction with the ability to quarantine/isolate infectious individuals.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Santiago</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutter</LastName><ForeName>Erica M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences Research Institute, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khatri</LastName><ForeName>Shilpa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences Research Institute, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sindi</LastName><ForeName>Suzanne S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0003-2742-4332</Identifier><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA. ssindi@ucmerced.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences Research Institute, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA. ssindi@ucmerced.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bull Math Biol</MedlineTA><NlmUniqueID>0401404</NlmUniqueID><ISSNLinking>0092-8240</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Global sensitivity analysis</Keyword><Keyword MajorTopicYN="N">ODE</Keyword><Keyword MajorTopicYN="N">SEIR</Keyword><Keyword MajorTopicYN="N">Sobol indices</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637563</ArticleId><ArticleId IdType="doi">10.1007/s11538-022-01107-2</ArticleId><ArticleId IdType="pii">10.1007/s11538-022-01107-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Archer G, Saltelli A, Sobol I (1997) Sensitivity measures, ANOVA-like techniques and the use of bootstrap. J Stat Comput Simul 58(2):99&#x2013;120</Citation></Reference><Reference><Citation>Backer JA, Klinkenberg D, Wallinga J (2020) Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20&#x2013;28 January 2020. Eurosurveillance 25(5):2000062</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.5.2000062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl R, Eikmeier N, Fraser A, Junge M, Keesing F, Nakahata K, Reeves L (2021) Modeling COVID-19 spread in small colleges. PLoS ONE 16(8):e0255654</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, Liu X, Wei L, Truelove SA, Zhang T et al (2020) Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis 20(8):911&#x2013;919</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30287-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Brlek A, Vidovi&#x10d; &#x160;, Vuzem S, Turk K, Simonovi&#x107; Z (2020) Possible indirect transmission of COVID-19 at a squash court, Slovenia, March 2020: case report. Epidemiol Infect 148</Citation></Reference><Reference><Citation>Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, Ciapponi A, Cevik M, Hauser A, Alam MI et al (2022) Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: update of a living systematic review and meta-analysis. PLoS Med 19(5):e1003987</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003987</ArticleId></ArticleIdList></Reference><Reference><Citation>Callimachi R (2021) For colleges, vaccine mandates often depend on which party is in power. https://www.nytimes.com/2021/05/22/us/college-vaccine-universities.html . Accessed 01 June 2021</Citation></Reference><Reference><Citation>Casey-Bryars M, Griffin J, McAloon C, Byrne A, Madden J, Mc Evoy D, Collins &#xc1;, Hunt K, Barber A, Butler F et al (2021) Presymptomatic transmission of SARS-CoV-2 infection: a secondary analysis using published data. BMJ Open 11(6):e041240</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-041240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, Piontti APY, Mu K, Rossi L, Sun K et al (2020) The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science 368(6489):395&#x2013;400</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba9757</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowell G, Brauer F (2009) The basic reproduction number of infectious diseases: computation and estimation using compartmental epidemic models, Mathematical and statistical estimation approaches in epidemiology. Springer, New York, pp 1&#x2013;30</Citation></Reference><Reference><Citation>Ellis L (2020) Colleges hoped for an in-person fall. Now the dream is crumbling. Chron High Educ</Citation></Reference><Reference><Citation>Gatto M, Bertuzzo E, Mari L, Miccoli S, Carraro L, Casagrandi R, Rinaldo A (2020) Spread and dynamics of the COVID-19 epidemic in Italy: effects of emergency containment measures. Proc Natl Acad Sci USA 117(19):10484&#x2013;10491</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2004978117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Bo&#xeb;lle PY, d&#x2019;Ortenzio E, Yazdanpanah Y, Eholie SP, Altmann M et al (2020) Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet 395(10227):871&#x2013;877</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30411-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass LM, Glass RJ (2008) Social contact networks for the spread of pandemic influenza in children and teenagers. BMC Public Health 8(1):1&#x2013;15</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-8-61</ArticleId></ArticleIdList></Reference><Reference><Citation>Gressman PT, Peck JR (2020) Simulating COVID-19 in a university environment. Math Biosci 328:108436</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mbs.2020.108436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamner L (2020) High SARS-CoV-2 attack rate following exposure at a choir practice&#x2014;Skagit County, Washington, March 2020. Morb Mortal Wkly Rep 69</Citation></Reference><Reference><Citation>Hethcote HW (2000) The mathematics of infectious diseases. SIAM Rev 42(4):599&#x2013;653</Citation><ArticleIdList><ArticleId IdType="doi">10.1137/S0036144500371907</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma T, Saltelli A (1996) Importance measures in global sensitivity analysis of nonlinear models. Reliab Eng Syst Saf 52(1):1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0951-8320(96)00002-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen HM, von Delft A, Price A, Fridman L, Tang LH, Tang V, Watson GL, Bax CE, Shaikh R, Questier F, Hernandez D, Chu LF, Ramirez CM, Rimoin AW (2021) An evidence review of face masks against COVID-19. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.2014564118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2014564118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivory D, Gebeloff R, Mervosh S (2021) Young people have less Covid-19 risk, but in college towns, deaths rose fast. https://www.nytimes.com/2020/12/12/us/covid-colleges-nursing-homes.html . Accessed 01 June 2021</Citation></Reference><Reference><Citation>Jansen MJ (1999) Analysis of variance designs for model output. Comput Phys Commun 117(1&#x2013;2):35&#x2013;43</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0010-4655(98)00154-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns Hopkins Corona Virus Response Center (2020) Corona virus resource center. COVID-19 Dashboard. https://coronavirus.jhu.edu/map.html . Accessed 13 Oct 2022</Citation></Reference><Reference><Citation>Ke R, Romero-Severson E, Sanche S, Hengartner N (2021) Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination. J Theor Biol 517:110621</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2021.110621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, Eggo RM (2020) Centre for mathematical modelling of infectious diseases COVID-19 working group. 2020, May. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect. Dis. 20(5):553&#x2013;558</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30144-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon KS, Park JI, Park YJ, Jung DM, Ryu KW, Lee JH (2020) Evidence of long-distance droplet transmission of SARS-CoV-2 by direct air flow in a restaurant in Korea. J Korean Med Sci 35(46)</Citation></Reference><Reference><Citation>Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 172(9):577&#x2013;582</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-0504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A (2021) A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 27(2):225&#x2013;228</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1124-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Hong CM, Kim DH, Lee TH, Lee J (2020) Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerg Infect Dis 26(10):2346</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201620</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung K, Jit M, Lau EH, Wu JT (2017) Social contact patterns relevant to the spread of respiratory infectious diseases in Hong Kong. Sci Rep 7(1):1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08241-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J (2020) Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 368(6490):489&#x2013;493</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3221</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Gayle AA, Wilder-Smith A, Rockl&#xf6;v J (2020) The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med</Citation></Reference><Reference><Citation>Lofgren E, Lum K, Horowitz A, Madubuonwu B, Myers K, Fefferman NH (2021) The epidemiological implications of jails for community, corrections officer, and incarcerated population risks from COVID-19. medRxiv. https://doi.org/10.1101/2020.04.08.20058842</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.08.20058842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopman B, Liu C, Le Guillou A, Handel A, Lash TL, Isakov A, Jenness S (2020) A model of COVID-19 transmission and control on university campuses. medRxiv. https://doi.org/10.1101/2020.06.23.20138677</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.23.20138677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rod&#xe9;s-Guirao L (2021) A global database of COVID-19 vaccinations. Nat Hum Behav 1&#x2013;7</Citation></Reference><Reference><Citation>MathWorks (2020) Statistics and machine learning Toolbox[Formula: see text] R2020a. https://www.mathworks.com/help/stats/</Citation></Reference><Reference><Citation>McCombs A, Kadelka C (2020) A model-based evaluation of the efficacy of COVID-19 social distancing, testing and hospital triage policies. PLoS Comput Biol 16(10):e1008388</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1008388</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizumoto K, Chowell G (2020) Transmission potential of the novel coronavirus (COVID-19) onboard the diamond Princess Cruises Ship, 2020. Infect Dis Model 5:264&#x2013;270</Citation></Reference><Reference><Citation>Moody J (2022) Colleges extend remote instruction. https://www.insidehighered.com/news/2022/01/10/colleges-extend-remote-instruction-period-due-omicron . Accessed 08 Feb 2022</Citation></Reference><Reference><Citation>Muniz-Rodriguez K, Chowell G, Cheung CH, Jia D, Lai PY, Lee Y, Liu M, Ofori SK, Roosa KM, Simonsen L et al (2020) Doubling time of the COVID-19 epidemic by province, China. Emerg Infect Dis 26(8):1912</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.200219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nierenberg A, Pasick A (2020) Schools briefing: coronavirus dorms and super spreaders. https://www.nytimes.com/2020/09/09/us/schools-reopening-coronavirus.html . Accessed 01 June 2021</Citation></Reference><Reference><Citation>Nunes-Vaz R (2020) Visualising the doubling time of COVID-19 allows comparison of the success of containment measures. Glob Biosecurity 1(3)</Citation></Reference><Reference><Citation>Oran DP, Topol EJ (2021) The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review. Ann Intern Med 174(5):655&#x2013;662</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-6976</ArticleId></ArticleIdList></Reference><Reference><Citation>Paltiel AD, Zheng A, Walensky RP (2020) Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. JAMA Netw Open 3(7):e2016818&#x2013;e2016818. https://doi.org/10.1001/jamanetworkopen.2020.16818</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.16818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Harb C, Leng W, Marr LC (2021) Inward and outward effectiveness of cloth masks, a surgical mask, and a face shield. Aerosol Sci Technol 55(6):718&#x2013;733</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02786826.2021.1890687</ArticleId></ArticleIdList></Reference><Reference><Citation>Panovska-Griffiths J, Stuart R, Kerr C, Rosenfield K, Mistry D, Waites W, Klein D, Bonell C, Viner R (2022) Modelling the impact of reopening schools in the UK in early 2021 in the presence of the alpha variant and with roll-out of vaccination against SARS-CoV-2. J Math Anal Appl 126050</Citation></Reference><Reference><Citation>Park M, Cook AR, Lim JT, Sun Y, Dickens BL (2020) A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med 9(4):967</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9040967</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SB, Patel P (2020) Doubling time and its interpretation for COVID 19 cases. Natl J Community Med 11:141&#x2013;143</Citation></Reference><Reference><Citation>Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, Singer BH, Galvani AP (2021) Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc Natl Acad Sci USA 118(34):e2109229118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109229118</ArticleId></ArticleIdList></Reference><Reference><Citation>Saltelli A, Ratto M, Andres T, Campolongo F, Cariboni J, Gatelli D, Saisana M, Tarantola S (2008) Global sensitivity analysis: the primer. Wiley, New Jersey</Citation></Reference><Reference><Citation>Saltelli A, Annoni P, Azzini I, Campolongo F, Ratto M, Tarantola S (2010) Variance based sensitivity analysis of model output. design and estimator for the total sensitivity index. Comput Phys Commun 181(2):259&#x2013;270</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpc.2009.09.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, Gibbs KW, Erickson HL, Steingrub JS, Smithline HA et al (2020) Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network-United States, March-June 2020. Morb Mortal Wkly Rep 69(30):993&#x2013;998</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend JP, Hassler HB, Sah P, Galvani AP, Dornburg A (2022) The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proc Natl Acad Sci USA 119(31):e2204336119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2204336119</ArticleId></ArticleIdList></Reference><Reference><Citation>Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PG, Fu H et al (2020) Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 20(6):669&#x2013;677</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30243-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeden KA, Cornwell B (2020) The small-world network of college classes: implications for epidemic spread on a university campus. Sociol Sci 7:222&#x2013;241</Citation><ArticleIdList><ArticleId IdType="doi">10.15195/v7.a9</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization March 11, 2020. WHO Director-General&#x2019;s opening remarks at the media briefing on COVID-19. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . Accessed 28 June 2020</Citation></Reference><Reference><Citation>Wrighton MS, Lawrence SJ (2020) Reopening colleges and universities during the COVID-19 pandemic. Ann Intern Med 173(8):664&#x2013;665</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-4752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng-Li S (2021) Origins of SARS-CoV-2: focusing on science. Infect Dis Immun 1(01):3&#x2013;4</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054&#x2013;1062</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637541</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1076</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>European journal of pediatrics</Title><ISOAbbreviation>Eur J Pediatr</ISOAbbreviation></Journal><ArticleTitle>Efficacy of transcutaneous posterior tibial nerve stimulation in functional constipation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00431-022-04798-w</ELocationID><Abstract><AbstractText Label="UNLABELLED">Most children with functional constipation (FC) improve with conventional treatments. However, a proportion of children have poor treatment outcomes. Management of intractable FC may include botulinum toxin injections, transanal irrigation, antegrade enemas, colonic resections, and in some cases sacral nerve stimulation (SNS). SNS is surgically placed, not readily available and expensive. Posterior tibial nerve stimulation (PTNS) allows transmission of electronic impulses and retrograde stimulation to the sacral nerve plexus in a portable, simple and non-invasive fashion. To assess the efficacy and safety of transcutaneous PTNS for the treatment of FC in children. Single-center, prospective interventional study. Children 4-14&#xa0;years with Rome IV diagnosis of FC received ten daily PTNS (30&#xa0;min/day) sessions. Electrodes placed over skin of ankle. Strength of stimulus was below pain threshold. Outcomes were assessed during treatment and 7&#xa0;days after. Twenty-three subjects enrolled. Two children excluded (acute gastroenteritis, COVID-19 contact). Twenty completed the study (4-14&#xa0;years), (8.4&#x2009;&#xb1;&#x2009;3.2&#xa0;years, 71.4% female). We found significant improvement in the consistency of bowel movements (BM) (p&#x2009;=&#x2009;0.005), fecal incontinence (FI) (p&#x2009;=&#x2009;0.005), abdominal pain presence (p&#x2009;=&#x2009;&lt;&#x2009;0.001) and intensity (p&#x2009;=&#x2009;0.005), and a significant for improvement in blood in stools (p&#x2009;=&#x2009;0.037). There was 86.3% improvement in abdominal pain. 96.7% reported treatment satisfaction. Only one child required rescue therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We found significant improvement in stool consistency, FI, abdominal pain, and hematochezia. This suggests that transcutaneous PTNS could be a promising noninvasive treatment for FC in children. Large studies are needed.</AbstractText><AbstractText Label="WHAT IS KNOWN" NlmCategory="BACKGROUND">&#x2022; Functional constipation is one of the most common disorders in children. &#x2022; Current management of functional constipation consists of an integrative approach that includes medications, diet and behavioral strategies.</AbstractText><AbstractText Label="WHAT IS NEW" NlmCategory="BACKGROUND">&#x2022; Posterior tibial nerve stimulation is a novel noninvasive and easy to use therapy that can improve stool consistency, fecal incontinence and blood in stools.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Velasco-Benitez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universidad del Valle, Calle 13 # 100-00, Cali Valle Del Cauca, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villamarin</LastName><ForeName>Eder</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Universidad del Valle, Calle 13 # 100-00, Cali Valle Del Cauca, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universidad del Valle, Calle 13 # 100-00, Cali Valle Del Cauca, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linero</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universidad Santiago de Cali, Cl. 5 #No. 62 -00, Cali, Valle del Cauca, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hungria</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Saps</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Miami, Mailman Center, 1601 NW 12 AVE, Suite 3005A, Miami, FL, 33136, USA. msaps@med.miami.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Pediatr</MedlineTA><NlmUniqueID>7603873</NlmUniqueID><ISSNLinking>0340-6199</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Constipation</Keyword><Keyword MajorTopicYN="N">Fecal incontinence</Keyword><Keyword MajorTopicYN="N">Gastrointestinal motility</Keyword><Keyword MajorTopicYN="N">Posterior tibial nerve</Keyword><Keyword MajorTopicYN="N">Transcutaneous electric nerve stimulation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637541</ArticleId><ArticleId IdType="doi">10.1007/s00431-022-04798-w</ArticleId><ArticleId IdType="pii">10.1007/s00431-022-04798-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koppen IJN, Vriesman MH, Saps M et al (2018) Prevalence of functional defecation disorders in children: a systematic review and meta-analysis. J Pediatr 198:121-130.e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2018.02.029</ArticleId></ArticleIdList></Reference><Reference><Citation>of the Nourth CG (2006) Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 43(3):e1&#x2013;13</Citation></Reference><Reference><Citation>Koppen IJN, Di Lorenzo C, Saps M et al (2016) Childhood Constipation: finally, something is moving! Expert Rev Gastroenterol Hepatol 10(1):141&#x2013;155</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/17474124.2016.1098533</ArticleId></ArticleIdList></Reference><Reference><Citation>Liem O, Harman J, Benninga M et al (2009) Health utilization and cost impact of childhood constipation in the United States. J Pediatr 154(2):258&#x2013;262</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2008.07.060</ArticleId></ArticleIdList></Reference><Reference><Citation>Madani S, Tsang L, Kamat D (2016) Constipation in children: a practical review. Pediatr Ann 1;45(5):e189&#x2013;196</Citation></Reference><Reference><Citation>Tabbers MM, DiLorenzo C, Berger MY et al (2014) Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 58(2):258&#x2013;274</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000266</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricard J, Qu&#xe9;n&#xe9;herv&#xe9; L, Lefevre C et al (2019) Anterograde Colonic irrigations by percutaneous endoscopic caecostomy in refractory colorectal functional disorders. Int J Colorectal Dis 34(1):169&#x2013;175</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-018-3183-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriesman MH, Wang L, Park C et al (2020) Comparison of antegrade continence enema treatment and sacral nerve stimulation for children with severe functional constipation and fecal incontinence. Neurogastroenterol Motil [Internet]. [cited 2020 Dec 6];32(8). Available from: https://onlinelibrary.wiley.com/doi/abs/ , https://doi.org/10.1111/nmo.13809</Citation></Reference><Reference><Citation>Heemskerk SCM, Rotteveel AH, Benninga MA et al (2018) Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis. Int J Colorectal Dis 33(4):493&#x2013;501</Citation></Reference><Reference><Citation>Lu PL, Koppen IJN, Orsagh-Yentis DK et al (2018) Sacral nerve stimulation for constipation and fecal incontinence in children: long-term outcomes, patient benefit, and parent satisfaction. Neurogastroenterol Motil 30(2):e13184</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13184</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriesman MH, Koppen IJN, Camilleri M et al (2020) Management of functional constipation in children and adults. Nat Rev Gastroenterol Hepatol 17(1):21&#x2013;39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0222-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco R, Braga A, Disanto G et al (2020) Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients. Mult Scler J 12:135245852097226</Citation></Reference><Reference><Citation>Altunrende B, Sengul N, Arisoy O et al (2013) Transcutaneous electrical posterior tibial nerve stimulation for chronic anal fissure: a preliminary study. Int J Colorectal Dis 28(11):1583&#x2013;1589</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-013-1743-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudaoud N, Binet A, Line A et al (2015) Management of refractory overactive bladder in children by transcutaneous posterior tibial nerve stimulation: a controlled study. J Pediatr Urol 11(3):138.e1-138.e10</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpurol.2014.09.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacic K, Sood MR, Mugie S et al (2015) A multicenter study on childhood constipation and fecal incontinence: effects on quality of life. J Pediatr 166(6):1482-1487.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2015.03.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushing CC, Martinez-Leo B, Bischoff A et al (2016) Health-Related quality of life and parental stress in children with fecal incontinence: a normative comparison. J Pediatr Gastroenterol Nutr 63(6):633&#x2013;636</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongers MEJ, van Dijk M, Benninga MA (2009) Health Related quality of life in children with constipation-associated fecal incontinence. J Pediatr 154(5):749-753.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2008.11.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lorenzo C, Nurko S, Hyams JS et al (2019) 1151 Linaclotide safety and efficacy in children aged 6 to 17 years with functional constipation. Am J Gastroenterol 114(1):S645&#x2013;S646</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/01.ajg.0000594132.11221.16</ArticleId></ArticleIdList></Reference><Reference><Citation>Mugie SM, Korczowski B, Bodi P et al (2014) Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology 147(6):1285-1295.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.09.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman PE, Di Lorenzo C, Prestridge LL et al (2014) Lubiprostone for the treatment of functional constipation in children: J Pediatr Gastroenterol Nutr 58(3):283&#x2013;291</Citation></Reference><Reference><Citation>Dinning PG, Hunt LM, Arkwright JW et al (2012) Pancolonic motor response to subsensory and suprasensory sacral nerve stimulation in patients with slow-transit constipation. Br J Surg 99(7):1002&#x2013;1010</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.8760</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas GP, Dudding TC, Rahbour G et al (2013) Sacral nerve stimulation for constipation. Br J Surg 100(2):174&#x2013;181</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.8944</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudding TC, Meng Lee E, Faiz O et al (2008) Economic evaluation of sacral nerve stimulation for faecal incontinence. Br J Surg 95(9):115</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.6237</ArticleId></ArticleIdList></Reference><Reference><Citation>Queralto M, Portier G, Cabarrot PH et al (2006) Preliminary results of peripheral transcutaneous neuromodulation in the treatment of idiopathic fecal incontinence. Int J Colorectal Dis 21(7):670&#x2013;672</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-005-0068-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Biemans JMAE, van Balken MR (2013) Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review: PTNS in the treatment of pelvic organ disorders. Neuromodulation Technol Neural Interface 16(1):25&#x2013;34</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1403.2012.00504.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal F, Collins B, Thomas GP et al (2016) Bilateral transcutaneous tibial nerve stimulation for chronic constipation. Colorectal Dis 18(2):173&#x2013;178</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/codi.13105</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lorenzo C, de Jong JR, Benninga MA (2017) Surgical management of children with intractable functional constipation; experience of a single tertiary children&#x2019;s hospital. Neurogastroenterol Motil 29(5):e13005</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637466</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2374-4243</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Infectious diseases (London, England)</Title><ISOAbbreviation>Infect Dis (Lond)</ISOAbbreviation></Journal><ArticleTitle>Novel clinical and immunological features associated with persistent post-acute sequelae of COVID-19 after six months of follow-up: a pilot study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>12</EndPage><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/23744235.2022.2158217</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Currently, there is scant information regarding the features associated to the persistence of post-COVID-19 syndrome, which is the main aim of the present study.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A cohort study of 102 COVID-19 patients was conducted. The post-COVID-19 symptoms were assessed by a standardised questionnaire. Lymphocyte immunophenotyping was performed by flow cytometry and chemokines/cytokines, neutrophil extracellular traps, the tripartite motif 63, anti-cellular, and anti-SARS-CoV-2 IgG antibodies were addressed in serum. The primary outcome was the persistence of post-COVID-19 syndrome after six months follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Thirteen patients (12.7%) developed the primary outcome and had a more frequent history of post-COVID-19 syndrome 3&#x2009;months after infection onset (<i>p</i>&#x2009;=&#x2009;.044), increased levels of IL-1&#x3b1; (<i>p</i>&#x2009;=&#x2009;.011) and IP-10 (<i>p</i>&#x2009;=&#x2009;.037) and increased CD57 expression in CD8<sup>+</sup> T cells (<i>p</i>&#x2009;=&#x2009;.003). There was a trend towards higher levels of IFN-&#x3b3; (<i>p</i>&#x2009;=&#x2009;.051), IL-1&#x3b2; (<i>p</i>&#x2009;=&#x2009;.062) and IL-6 (<i>p</i>&#x2009;=&#x2009;.087). The history of post COVID-19 in the previous 3&#x2009;months, obesity, baseline serum MIP-1&#x3b1; and IP-10, and CD57 expression in CD8<sup>+</sup> T cells were independently associated with the persistence of post-COVID-19 syndrome.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our data suggest an important relationship between a pro-inflammatory state mediated through metabolic pathways related to obesity and increased cellular senescence as a key element in the persistence of post-COVID-19 syndrome at six months of follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torres-Ruiz</LastName><ForeName>Jiram</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomel&#xed;n-Gasc&#xf3;n</LastName><ForeName>Julieta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lira Luna</LastName><ForeName>Jaquelin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Secci&#xf3;n de Estudios de Posgrado e Investigaci&#xf3;n Escuela Superior de Medicina-IPN, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas-Castro</LastName><ForeName>Ana Sofia</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Becaria o Becario de la Direcci&#xf3;n General de Calidad y Educaci&#xf3;n en Salud, Secretar&#xed;a de Salud, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Fragoso</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Inmunoqu&#xed;mica 1, Posgrado en Ciencias Qu&#xed;micobiol&#xf3;gicas, Escuela Nacional de Ciencias Biol&#xf3;gicas, Instituto Polit&#xe9;cnico Nacional.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nu&#xf1;ez-Aguirre</LastName><ForeName>Miroslava</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Inmunoqu&#xed;mica 1, Posgrado en Ciencias Qu&#xed;micobiol&#xf3;gicas, Escuela Nacional de Ciencias Biol&#xf3;gicas, Instituto Polit&#xe9;cnico Nacional.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcal&#xe1;-Carmona</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Inmunoqu&#xed;mica 1, Posgrado en Ciencias Qu&#xed;micobiol&#xf3;gicas, Escuela Nacional de Ciencias Biol&#xf3;gicas, Instituto Polit&#xe9;cnico Nacional.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Absal&#xf3;n-Aguilar</LastName><ForeName>Abdiel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balderas-Miranda</LastName><ForeName>Jennifer T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Program of Combined Studies in Medicine, School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maravillas-Montero</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mej&#xed;a-Dom&#xed;nguez</LastName><ForeName>Nancy R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfa;&#xf1;ez-&#xc1;lvarez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorente</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-Ram&#xed;rez</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sosa-Hern&#xe1;ndez</LastName><ForeName>Victor Andr&#xe9;s</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervantes-D&#xed;az</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju&#xe1;rez-Vega</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meza-S&#xe1;nchez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rull-Gabayet</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Ju&#xe1;rez</LastName><ForeName>Luis Alberto</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temporary COVID-19 Hospital, Hip&#xf3;dromo de las Am&#xe9;ricas, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-L&#xf3;pez</LastName><ForeName>Lizeth Naomi</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negrete-Trujillo</LastName><ForeName>Jos&#xe9; Adri&#xe1;n</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falc&#xf3;n-Lezama</LastName><ForeName>Jorge Abelardo</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Divisi&#xf3;n Acad&#xe9;mica de Ciencias de la Salud, Universidad Ju&#xe1;rez Aut&#xf3;noma de Tabasco, Villahermosa, Tabasco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdez-V&#xe1;zquez</LastName><ForeName>Rafael Ricardo</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Temporary COVID-19 Hospital, Hip&#xf3;dromo de las Am&#xe9;ricas, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo-Rinc&#xf3;n</LastName><ForeName>H&#xe9;ctor</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapia-Conyer</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Autonomous University of Mexico, School of Medicine, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Mart&#xed;n</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1807-0045</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Infect Dis (Lond)</MedlineTA><NlmUniqueID>101650235</NlmUniqueID><ISSNLinking>2374-4243</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IP-10</Keyword><Keyword MajorTopicYN="N">MIP-1&#x3b1;</Keyword><Keyword MajorTopicYN="N">Persistent PASC</Keyword><Keyword MajorTopicYN="N">immunoinflamation</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">senescence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637466</ArticleId><ArticleId IdType="doi">10.1080/23744235.2022.2158217</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637405</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>The Modified and Extended Hospital Elder Life Program: A remote model of care to expand delirium prevention.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.18212</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Delirium is a common complication of hospitalization and is associated with poor outcomes. Multicomponent delirium prevention strategies such as the Hospital Elder Life Program (HELP) have proven effective but rely on face-to-face intervention protocols and volunteer staff, which was not possible due to restrictions during the COVID-19 pandemic. We developed the Modified and Extended Hospital Elder Life Program (HELP-ME), an innovative adaptation of HELP for remote and/or physically distanced applications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">HELP-ME protocols were adapted from well-established multicomponent delirium prevention strategies and were implemented at four expert HELP sites. Each site contributed to the protocol modifications and compilation of a HELP-ME Operations Manual with standardized protocols and training instructions during three expert panel working groups. Implementation was overseen and monitored during seven learning sessions plus four coaching sessions from January 8, 2021, through September 24, 2021. Feasibility of implementing HELP-ME was measured by protocol adherence rates. Focus groups were conducted to evaluate the acceptability, provide feedback, and identify facilitators and barriers to implementation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 106 patients were enrolled across four sites, and data were collected for 214 patient-days. Overall adherence was 82% (1473 completed protocols/1798 patient-days), achieving our feasibility target of &gt;75% overall adherence. Individual adherence rates ranged from 55% to 96% across sites for the individual protocols. Protocols with high adherence rates included the nursing delirium protocol (96%), nursing medication review (96%), vision (89%), hearing (87%), and orientation (88%), whereas lower adherence occurred with fluid repletion (64%) and range-of-motion exercises (55%). Focus group feedback was generally positive for acceptability, with recommendations that an optimal approach would be hybrid, balancing in-person and remote interventions for potency and long-term sustainability.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HELP-ME was fully implemented at four HELP sites, demonstrating feasibility and acceptability. Testing hybrid approaches and evaluating effectiveness is recommended for future work.</AbstractText><CopyrightInformation>&#xa9; 2023 The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Tamara G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aging Brain Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albaum</LastName><ForeName>Jason A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Biochemistry Program, Vassar College, Poughkeepsie, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Molly L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Maine Medical Center, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Sara G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center, Sutter Health, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Shauni</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Primary Care Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Supiano</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-5438-5087</Identifier><AffiliationInfo><Affiliation>Geriatrics Division, University of Utah School of Medicine and University of Utah Center on Aging, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlisides</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Consciousness Science, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wade</LastName><ForeName>Harley L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Maine Medical Center, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Lyn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Primary Care Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wierman</LastName><ForeName>Heidi R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Maine Medical Center, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachary</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center, Sutter Health, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inouye</LastName><ForeName>Sharon K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Aging Brain Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HELP-ME Writing Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R33AG071744</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">delirium</Keyword><Keyword MajorTopicYN="N">delirium prevention</Keyword><Keyword MajorTopicYN="N">multicomponent</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>10</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637405</ArticleId><ArticleId IdType="doi">10.1111/jgs.18212</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wilson JE, Mart MF, Cunningham C, et al. Delirium. Nat Rev Dis Primers. 2020;6:90.</Citation></Reference><Reference><Citation>Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008;168:27-32.</Citation></Reference><Reference><Citation>Hshieh TT, Inouye SK, Oh ES. Delirium in the elderly. Clin Geriatr Med. 2020;36:183-199.</Citation></Reference><Reference><Citation>Hshieh TT, Yue J, Oh E, et al. Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis. JAMA Intern Med. 2015;175:512-520.</Citation></Reference><Reference><Citation>Khan A, Boukrina O, Oh-Park M, Flanagan NA, Singh M, Oldham M. Preventing delirium takes a village: systematic review and meta-analysis of delirium preventive models of care. J Hosp Med. 2019;14:E1-e7.</Citation></Reference><Reference><Citation>Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340:669-676.</Citation></Reference><Reference><Citation>Hshieh TT, Yang T, Gartaganis SL, Yue J, Inouye SK. Hospital Elder Life Program: systematic review and meta-analysis of effectiveness. Am J Geriatr Psychiatry. 2018;26:1015-1033.</Citation></Reference><Reference><Citation>Inouye SK, Bogardus ST Jr, Baker DI, Leo-Summers L, Cooney LM Jr. The Hospital Elder Life Program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program. J Am Geriatr Soc. 2000;48:1697-1706.</Citation></Reference><Reference><Citation>Rubin FH, Neal K, Fenlon K, Hassan S, Inouye SK. Sustainability and scalability of the Hospital Elder Life Program at a community hospital. J Am Geriatr Soc. 2011;59:359-365.</Citation></Reference><Reference><Citation>Rubin FH, Williams JT, Lescisin DA, Mook WJ, Hassan S, Inouye SK. Replicating the Hospital Elder Life Program in a community hospital and demonstrating effectiveness using quality improvement methodology. J Am Geriatr Soc. 2006;54:969-974.</Citation></Reference><Reference><Citation>Caplan GA, Harper EL. Recruitment of volunteers to improve vitality in the elderly: the REVIVE study. Intern Med J. 2007;37:95-100.</Citation></Reference><Reference><Citation>Rubin FH, Bellon J, Bilderback A, Urda K, Inouye SK. Effect of the Hospital Elder Life Program on risk of 30-day readmission. J Am Geriatr Soc. 2018;66:145-149.</Citation></Reference><Reference><Citation>Zachary W, Kirupananthan A, Cotter S, Barbara GH, Cooke RC 3rd, Sipho M. The impact of Hospital Elder Life Program interventions, on 30-day readmission rates of older hospitalized patients. Arch Gerontol Geriatr. 2020;86:103963.</Citation></Reference><Reference><Citation>Wang YY, Yue JR, Xie DM, et al. Effect of the tailored, family-involved Hospital Elder Life Program on postoperative delirium and function in older adults: a randomized clinical trial. JAMA Intern Med. 2020;180:17-25.</Citation></Reference><Reference><Citation>Chen CC, Li HC, Liang JT, et al. Effect of a modified Hospital Elder Life Program on delirium and length of hospital stay in patients undergoing abdominal surgery: a cluster randomized clinical trial. JAMA Surg. 2017;152:827-834.</Citation></Reference><Reference><Citation>Simpson M, Macias Tejada J, Driscoll A, Singh M, Klein M, Malone M. The bundled Hospital Elder Life Program-HELP and HELP in home care-and its association with clinical outcomes among older adults discharged to home healthcare. J Am Geriatr Soc. 2019;67:1730-1736.</Citation></Reference><Reference><Citation>Boockvar KS, Judon KM, Eimicke JP, Teresi JA, Inouye SK. Hospital Elder Life Program in long-term care (HELP-LTC): a cluster randomized controlled trial. J Am Geriatr Soc. 2020;68:2329-2335.</Citation></Reference><Reference><Citation>Boockvar KS, Teresi JA, Inouye SK. Preliminary data: an adapted Hospital Elder Life Program to prevent delirium and reduce complications of acute illness in long-term care delivered by certified nursing assistants. J Am Geriatr Soc. 2016;64:1108-1113.</Citation></Reference><Reference><Citation>Huson K, Stolee P, Pearce N, Bradfield C, Heckman GA. Examining the Hospital Elder Life Program in a rehabilitation setting: a pilot feasibility study. BMC Geriatr. 2016;16:140.</Citation></Reference><Reference><Citation>Kojaie-Bidgoli A, Sharifi F, Maghsoud F, Alizadeh-Khoei M, Jafari F, Sadeghi F. The modified Hospital Elder Life Program (HELP) in geriatric hospitalized patients in internal wards: a double-blind randomized control trial. BMC Geriatr. 2021;21:599.</Citation></Reference><Reference><Citation>Gan JM, Kho J, Akhunbay-Fudge M, et al. Atypical presentation of COVID-19 in hospitalised older adults. Ir J Med Sci. 2021;190:469-474.</Citation></Reference><Reference><Citation>O'Hanlon S, Inouye SK. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. 2020;49:497-498.</Citation></Reference><Reference><Citation>Ward CF, Figiel GS, McDonald WM. Altered mental status as a novel initial clinical presentation for COVID-19 infection in the elderly. Am J Geriatr Psychiatry. 2020;28:808-811.</Citation></Reference><Reference><Citation>Dalkey N, Helmer O. An experimental application of the DELPHI method to the use of experts. Manag Sci. 1963;9:458-467.</Citation></Reference><Reference><Citation>Inouye SK. The importance of delirium and delirium prevention in older adults during lockdowns. JAMA. 2021;325:1779-1780.</Citation></Reference><Reference><Citation>Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113:941-948.</Citation></Reference><Reference><Citation>Fick DM, Inouye SK, Guess J, et al. Preliminary development of an ultrabrief two-item bedside test for delirium. J Hosp Med. 2015;10:645-650.</Citation></Reference><Reference><Citation>Fick DM, Inouye SK, McDermott C, et al. Pilot study of a two-step delirium detection protocol administered by certified nursing assistants, physicians, and registered nurses. J Gerontol Nurs. 2018;44:18-24.</Citation></Reference><Reference><Citation>Husser EK, Fick DM, Boltz M, et al. Implementing a rapid, two-step delirium screening protocol in acute care: barriers and facilitators. J Am Geriatr Soc. 2021;69:1349-1356.</Citation></Reference><Reference><Citation>Motyl CM, Ngo L, Zhou W, et al. Comparative accuracy and efficiency of four delirium screening protocols. J Am Geriatr Soc. 2020;68:2572-2578.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637383</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2463-0225</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Revista colombiana de obstetricia y ginecologia</Title><ISOAbbreviation>Rev Colomb Obstet Ginecol</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>408</StartPage><EndPage>409</EndPage><MedlinePgn>408-409</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18597/rcog.3978</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fl&#xf3;rez-Victoria</LastName><ForeName>Orlando Javier</ForeName><Initials>OJ</Initials><AffiliationInfo><Affiliation>Federaci&#xf3;n Colombiana de Obstetricia y Ginecolog&#xed;a, Bogot&#xe1; (Colombia). fecolsog@fecolsog.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Carta al editor en relaci&#xf3;n con el art&#xed;culo titulado: Reflexiones acerca del desempe&#xf1;o del ministro de Salud de Colombia en el manejo de la pandemia de COVID-19, la salud sexual y reproductiva, y la salud p&#xfa;blica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Rev Colomb Obstet Ginecol</MedlineTA><NlmUniqueID>0404263</NlmUniqueID><ISSNLinking>0034-7434</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637383</ArticleId><ArticleId IdType="doi">10.18597/rcog.3978</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637379</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1931-7913</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>CBE life sciences education</Title><ISOAbbreviation>CBE Life Sci Educ</ISOAbbreviation></Journal><ArticleTitle>Costs and Benefits of Undergraduates Revealing Depression to Online Science Instructors.</ArticleTitle><Pagination><StartPage>ar9</StartPage><MedlinePgn>ar9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1187/cbe.22-05-0088</ELocationID><Abstract><AbstractText>Depression is one of the leading mental health concerns among science undergraduates, and rates of student depression increased during the COVID-19 pandemic. Revealing one's depression in an academic science environment can be helpful, because it can result in increased support from others. However, depression is considered a concealable stigmatized identity, meaning that it can be kept hidden and may carry a stigma. A national pivot to online learning owing to COVID-19 not only increased the need to bolster student mental health, but also presented a novel learning environment. However, it is unclear to what extent students revealed their depression in science courses and why. We surveyed 1179 undergraduates with depression at a research-intensive institution about whether they had revealed their depression to an online college science instructor. Very few undergraduates (5.9%) had revealed their depression to online science instructors; students who identify as LGBTQ+, have lower grade point averages, or experience more severe depression were more likely to reveal their depression to an instructor. Undergraduates reported potential benefits from doing so, including building a connection with the instructor and receiving accommodations. This work provides insight into steps science instructors can take to foster inclusive course environments for students with depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Carly A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Research for Inclusive STEM Education Center, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Tasneem F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Research for Inclusive STEM Education Center, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadile</LastName><ForeName>Erika M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witt</LastName><ForeName>Madison L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Missy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Joseph Gazing</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Research for Inclusive STEM Education Center, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brister</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Katelyn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Research for Inclusive STEM Education Center, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CBE Life Sci Educ</MedlineTA><NlmUniqueID>101269039</NlmUniqueID><ISSNLinking>1931-7913</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637379</ArticleId><ArticleId IdType="doi">10.1187/cbe.22-05-0088</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>